BioSim participated in the public consultation process, which began at the beginning of 2021, in which it exposed the need to commit to strong incentive policies towards biosimilar medicines, both in the hospital setting and in Primary Care.
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
